Cargando…

Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community

BACKGROUND: Medical products are an integral and pivotal part of health care delivery. They need to be available, affordable and quality-assured. The SADC region is prone to threats arising from the availability and use of substandard and falsified (SF) medical products. This is something that needs...

Descripción completa

Detalles Bibliográficos
Autores principales: Kniazkov, Stanislav, Dube-Mwedzi, Sakhile, Nikiema, Jean-Baptiste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574476/
https://www.ncbi.nlm.nih.gov/pubmed/33088577
http://dx.doi.org/10.1186/s40545-020-00257-9
_version_ 1783597645387792384
author Kniazkov, Stanislav
Dube-Mwedzi, Sakhile
Nikiema, Jean-Baptiste
author_facet Kniazkov, Stanislav
Dube-Mwedzi, Sakhile
Nikiema, Jean-Baptiste
author_sort Kniazkov, Stanislav
collection PubMed
description BACKGROUND: Medical products are an integral and pivotal part of health care delivery. They need to be available, affordable and quality-assured. The SADC region is prone to threats arising from the availability and use of substandard and falsified (SF) medical products. This is something that needs to be actively addressed. METHOD: A survey, constructed around four themes, was carried out between September 2018 and January 2019. The National Medicines Regulatory Authorities (NMRAs) of the 16 Member States within the SADC region were asked to respond to the survey questionnaire. The objective was to map existing fameworks, mechanisms and approaches to prevention, detection and response (PDR) to SF medical products. RESULTS: Responses were received from twelve out of the sixteen NMRAs. Only three of the twelve respondents had included elements for PDR for SF medical products in their national medicine policies. Regardless of the status in terms of policies, legislation is however in place for the majority of NMRAs. The mandate for regular sampling, an important detection mechanism, was enshrined in the legislation of nine of the twelve respondents. In terms of response mechanisms, six of the respondents had both inter-agency and intra-agency co-ordination for responding to SF products. CONCLUSION: Though findings point to some deficiencies in terms of policies and implementation plans, the majority of countries have the mandate and legislation to deal with substandard and falsified medical products. Effective enforcement requires more investments into human resources, infrastructure, stakeholder coordination and public outreach. WHO has an important source of actionable information about incidience of substandard and falsified medical products. It needs to be leveraged to improve outreach to stakeholders and to raise awareness about SF problem and mechanisms available to address it. The extent, to which mechanisms and procedures are in place, varies. Some elements of the desired approach exist in the region; however, they will benefit from targeted strengthening to ensure a holistic approach across 12 action areas recommended by WHO.
format Online
Article
Text
id pubmed-7574476
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75744762020-10-20 Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community Kniazkov, Stanislav Dube-Mwedzi, Sakhile Nikiema, Jean-Baptiste J Pharm Policy Pract Review BACKGROUND: Medical products are an integral and pivotal part of health care delivery. They need to be available, affordable and quality-assured. The SADC region is prone to threats arising from the availability and use of substandard and falsified (SF) medical products. This is something that needs to be actively addressed. METHOD: A survey, constructed around four themes, was carried out between September 2018 and January 2019. The National Medicines Regulatory Authorities (NMRAs) of the 16 Member States within the SADC region were asked to respond to the survey questionnaire. The objective was to map existing fameworks, mechanisms and approaches to prevention, detection and response (PDR) to SF medical products. RESULTS: Responses were received from twelve out of the sixteen NMRAs. Only three of the twelve respondents had included elements for PDR for SF medical products in their national medicine policies. Regardless of the status in terms of policies, legislation is however in place for the majority of NMRAs. The mandate for regular sampling, an important detection mechanism, was enshrined in the legislation of nine of the twelve respondents. In terms of response mechanisms, six of the respondents had both inter-agency and intra-agency co-ordination for responding to SF products. CONCLUSION: Though findings point to some deficiencies in terms of policies and implementation plans, the majority of countries have the mandate and legislation to deal with substandard and falsified medical products. Effective enforcement requires more investments into human resources, infrastructure, stakeholder coordination and public outreach. WHO has an important source of actionable information about incidience of substandard and falsified medical products. It needs to be leveraged to improve outreach to stakeholders and to raise awareness about SF problem and mechanisms available to address it. The extent, to which mechanisms and procedures are in place, varies. Some elements of the desired approach exist in the region; however, they will benefit from targeted strengthening to ensure a holistic approach across 12 action areas recommended by WHO. BioMed Central 2020-10-20 /pmc/articles/PMC7574476/ /pubmed/33088577 http://dx.doi.org/10.1186/s40545-020-00257-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Kniazkov, Stanislav
Dube-Mwedzi, Sakhile
Nikiema, Jean-Baptiste
Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community
title Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community
title_full Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community
title_fullStr Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community
title_full_unstemmed Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community
title_short Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community
title_sort prevention, detection and response to incidences of substandard and falsified medical products in the member states of the southern african development community
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574476/
https://www.ncbi.nlm.nih.gov/pubmed/33088577
http://dx.doi.org/10.1186/s40545-020-00257-9
work_keys_str_mv AT kniazkovstanislav preventiondetectionandresponsetoincidencesofsubstandardandfalsifiedmedicalproductsinthememberstatesofthesouthernafricandevelopmentcommunity
AT dubemwedzisakhile preventiondetectionandresponsetoincidencesofsubstandardandfalsifiedmedicalproductsinthememberstatesofthesouthernafricandevelopmentcommunity
AT nikiemajeanbaptiste preventiondetectionandresponsetoincidencesofsubstandardandfalsifiedmedicalproductsinthememberstatesofthesouthernafricandevelopmentcommunity